evamizole in treatment of COVID19.
Not Applicable
Recruiting
- Conditions
- COVID19.U07.1 COVID-19, virus identified•U07.2 COVID-19, virus not identifiedoClinically-epidemiologically diagnosed COVID-19oProbable COVID-19 oSuspected COVID-19U07.1
- Registration Number
- IRCT20181208041886N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
age =or > 18 years
Diagnosis of COVID19 infection was made by positive test for RtPCR on nasopharyngeal swab, Lung HRCT and the opinion of infectious diseases specialist.
informed consent of patient for study
the possibility of patient follow up.
Exclusion Criteria
Another cause for signs and symptoms
hypersensitivity to levamizole
consumption of other antibiotics on the neck.
Dyspnea
Pregnancy
breat feeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Discontinuation of fever. Timepoint: Daily. Method of measurement: evaluation by a physician.;Improvement of dyspnea. Timepoint: Daily. Method of measurement: evaluation by physician.;Decreasing of cogh. Timepoint: Daily. Method of measurement: evaluation by physician.;Elevation of O2sat of the blood. Timepoint: Daily. Method of measurement: evaluation by physician.;Blood presure improvement. Timepoint: Daily. Method of measurement: evaluation by physician.;Pulse rate improvement. Timepoint: Daily. Method of measurement: evaluation by physician.
- Secondary Outcome Measures
Name Time Method Improvement of the patient which has had COVOD-19>. Timepoint: 14 days. Method of measurement: evaluation of the patient by a physician.